Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck - A Southwest Oncology Group trial

Sarah A. Taylor, Jacqueline Benedetti, David Schuller, Stephen P Richman, Goronwy O. Broun, Alexander Hantel

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Twenty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with piroxantrone 150 mg/m2 intravenously every 21 days. There were no objective responses. The 95% upper confidence bound for response is 15%. Primary toxicity was hematologic.

Original languageEnglish
Pages (from-to)227-229
Number of pages3
JournalInvestigational New Drugs
Volume11
Issue number2-3
DOIs
StatePublished - Jun 1 1993

    Fingerprint

Keywords

  • piroxantrone
  • squamous cell of head and neck

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this